Aim: This study aimed to evaluate the relationship between serum uric acid (SUA) level and non-alcoholic fatty liver disease (NAFLD) in non-obese adults.
Results:
The overall prevalence of NAFLD was 39.51% in the study group, and 14.88% in non-obese adults. The NAFLD patients had significantly higher SUA levels than controls in both men and women. The non-obese group had a higher NAFLD risk with increased SUA levels than the obese group, with odd ratios (95% confidence interval) of 2.559 (1.870-3.503) and 1.692 (1.371-2.087), respectively. In 93 non-obese adults with biopsyproven NAFLD, SUA levels were significantly higher in those with non-alcoholic steatohepatitis. The prevalence of non-alcoholic steatohepatitis and lobule inflammation tended to increase to 57.58% and 66.67% as the SUA level increased to the fourth quartile. Subjects with hyperuricemia had significantly higher NAFLD activity scores and more serious lobule inflammation than the normal group.
INTRODUCTION
N ON-ALCOHOLIC FATTY LIVER disease (NAFLD) is characterized by significant lipid deposition, usually greater than 5% of the liver weight deposited as triglyceride, in the liver parenchyma, without history of excessive alcohol consumption. The NAFLD spectrum ranges from simple steatosis (non-alcoholic fatty liver), to nonalcoholic steatohepatitis (NASH), to cirrhosis, ultimately developing into hepatocellular carcinoma. 1 Nowadays, NAFLD is not only the most common liver disease in Europe and North America, but also becoming increasingly prevalent in the Asia-Pacific region, especially in China with the prevalence of 15-30% in the general population. 2 Non-alcoholic fatty liver disease mainly occurs in obese individuals, but recent studies revealed that NAFLD is also not rare in non-obese adults. 3 The prevalence of NAFLD in non-obese adults was 15.2% in a Japanese study group. 4 So it is time to pay attention to NAFLD in nonobese adults.
There is growing evidence that serum uric acid (SUA) level, the final product of purine degradation, is elevated in metabolic syndrome (MetS) and strongly associated with insulin resistance. The level of SUA is maintained by the balance between uric acid production and excretion in physiological conditions. However, the prevalence and incidence of hyperuricemia in the world population have steadily increased over the past 40 years. 5 Although uric acid is recognized as an antioxidant, hyperuricemia has been implicated in the development of gout, coronary artery disease, type 2 diabetes, MetS, and NAFLD. [6] [7] [8] [9] Increased SUA has been linked to increased oxidative stress, chronic low grade inflammation, and insulin resistance, 10, 11 which are the basic pathophysiology of NAFLD.
Although numerous studies have reported that SUA level is associated with NAFLD, 12, 13 no study has aimed to investigate the association of SUA level with NAFLD and its inflammation progression in non-obese adults. This study aimed to investigate the clinical and histopathologic characteristics of NAFLD, and then analyze the relationships between SUA, NAFLD, and degree of inflammation in non-obese adults.
MATERIALS AND METHODS

Study design and subjects
A CROSS-SECTIONAL STUDY was carried out to evaluate the relationship between SUA level and NAFLD. This study initially enrolled all of the adults who took their health examination at Xixi Hospital (Hangzhou, China) and the Affiliated Hospital of Hangzhou Normal University (Hangzhou, China) between January 1, 2013 and December 31, 2014. Subjects meeting the following criteria were excluded: (i) those taking antihypertensive or antidiabetic agents, lipid-lowering agents, or hypouricemic agents; (ii) those with alcohol consumption greater than 140 g/week for men and 70 g/week for women; (iii) those with a history of other known causes of chronic liver disease, such as viral hepatitis or autoimmune hepatitis, and (iv) those using hepatotoxic medications. A total of 4098 eligible subjects were enrolled. An additional 93 nonobese adults with biopsy-proven NAFLD were also included. The study protocol was approved by the ethics committee, complying with the ethical guidelines of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). And written informed consent was obtained from all subjects.
Clinical examination and biochemical analyses
All participants underwent routine medical history and physical examination including blood pressure measurement, anthropometry, and laboratory assessments. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared (kg/m 2 ) and used as an index of body fat. Clinical examinations were undertaken in the morning after an overnight fast, and subjects were also instructed to refrain from exercise during the day prior to their examination. The examination consisted of a physical examination and a health habit inventory by a physician.
Fasting blood samples were obtained from an antecubital vein, and the samples were used for the analysis of biochemical values. The values included alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), lowdensity lipoprotein cholesterol (LDL-C), cglutamyltransferase, SUA, and fasting plasma glucose (FPG) . All values were measured by an automatic biochemical analyzer (model 7180; Hitachi, Tokyo, Japan) using standard methods.
Ultrasonography
Hepatic ultrasonic examination was carried out in all subjects by two trained ultrasound doctors who were blinded to the clinical and laboratory data, using a Toshiba Nemio 20 sonography machine (Toshiba, Tokyo, Japan) with a 3.5-MHz probe. Hepatic steatosis was diagnosed by characteristic echo patterns according to conventional criteria, such as the evidence of diffuse hyperechogenicity of the liver relative to the kidneys, ultrasound beam attenuation, and poor visualization of intrahepatic structures. 14 
Liver histology
The histopathological diagnosis of NAFLD was established by two expert liver pathologist, blinded to subjects' details. Liver biopsy specimens were scored using the NASH CRN scoring system. 15 In brief, the degree of steatosis, liver injury, and inflammatory activity were scored using an 8-point scale: steatosis, 0-3; lobular inflammation, 0-3; ballooning hepatocyte degeneration, 0-2. The stage of fibrosis was scored using a 6-point scale: 1a, mild zone 3 perisinusoidal fibrosis; 1b, moderate zone 3 perisinusoidal fibrosis; 1c, portal fibrosis only; 2, zone 3 and portal/periportal fibrosis; 3, bridging fibrosis; 4, cirrhosis. In addition to determining the NAFLD activity score (NAS), an overall diagnostic categorization was determined for each case as simple steatosis (NAS, 0-2), indefinite NASH (NAS, 3-4), and NASH (NAS, [5] [6] [7] [8] . According to the fibrosis stage, cases were divided into non-advanced fibrosis (stage of fibrosis, 0-2) and advanced fibrosis.
Definitions and statistical analyses
Non-alcoholic fatty liver disease was diagnosed by abdominal ultrasound following exclusion of alcohol consumption and viral or autoimmune liver disease. 16, 17 A BMI of ≥18.5 kg/m 2 and <25 kg/m 2 for non-obese subjects, and BMI ≥25 kg/m2 for obese subjects was defined according to the World Health Organization guidelines of categorizing obesity in Asian populations as proposed in 2000. Hyperuricemia was defined as an SUA level >420 μmol/L in male subjects and >360 μmol/L in female subjects. Statistical analyses were carried out using the SPSS software package version 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous variables are presented as the mean and standard deviation (SD) or the median and interquartile range (IQR), as appropriate. Student's t-test or the Mann-Whitney U-test was used for two-group comparisons of continuous data; categorical variables were compared using the χ 2 -test. One-way ANOVA followed by Dunnett's test was used for multiple group comparisons. Linear correlation analysis was used to determine the relationship between SUA level and other parameters of NAFLD patients. Multivariate logistic regression (backward Wald; entry, 0.05; removal, 0.10) was used to evaluate the risk factors for NAFLD. P < 0.05 was considered statistically significant.
RESULTS
Clinical and laboratory characteristics of subjects O F 4098 SUBJECTS enrolled in this study, 1619 (39.51%) fulfilled NAFLD diagnostic criteria. Anthropometric, clinical, and laboratory data of 4098 subjects are shown in Table 1 . Compared with healthy subjects, NAFLD patients were older, had significantly higher BMI, FPG, TG, TC, LDL-C, ALT, AST, serum creatinine (SCr), blood urea nitrogen (BUN), and SUA levels, and lower HDL-C levels.
There were 1936 non-obese subjects (18.5 ≤ BMI < 25 kg/m2) and 2162 obesity subjects (BMI ≥ 25 kg/m2). The prevalence of NAFLD was 14.88% (288/1936) in the non-obese group, and 61.56% in the obese group. In the non-obese study group, NAFLD patients were older, and they had significantly higher BMI, FPG, TG, TC, LDL-C, ALT, AST, SCr, and BUN levels, and lower HDL-C levels than controls. Notably, significantly higher SUA levels were observed in subjects with NAFLD than in those without NAFLD in the non-obese group (men, 368.00 ± 75.45 vs. 332.72 ± 72.82 μmol/L; women, 272.00 ± 71.84 vs. 232.46 ± 54.72 μmol/L) (Fig. 1a) . Compared with NAFLD patients in the obese group, non-obese patients were older and had significantly lower BMI, TG, ALT, SCr, and SUA levels ( Table 2) . In female subjects, Data are expressed as mean ± standard deviation or median (interquartile range). ‡P-value calculated using the Mann-Whitney U-test. †P-value calculated using the χ 2 -test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SCr, serum creatinine; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride.
SUA level increased with age in both non-obese and obese groups. Among non-obese NAFLD patients, women after menopause had significantly higher SUA levels than women before menopause (286.44 ± 63.60 vs. 254.96 ± 70.88 μmol/L) (Fig. 1b) .
Association between SUA and other clinical parameters
Linear correlation analysis was used to determine the relationship between SUA level and other clinical parameters. Eleven variables including age, BMI, TG, TC, HDL-C, LDL-C, ALT, AST, FPG, SCr, and BUN were involved (Table 3 ). There were extremely significant positive correlations between BMI, TG, TC, LDL-C, ALT, AST, SCr, BUN and SUA, whereas HDL-C had negative correlations in both non-obese and obese subject groups. Remarkably, compared with the obese group, the correlation coefficients between BMI, TG, TC, LDL-C, HDL-C, ALT, SCr, BUN, and SUA were all higher in the non-obese group. , Nonobese NAFLD Present; , Obesity NAFLD Present; , Obesity NAFLD Absent. -test. ‡For comparison of non-obese subjects and obese subjects with NALFD, P < 0.05. §P-value calculated using the Mann-Whitney U-test. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SCr, serum creatinine; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride.
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Risk factors analysis for NAFLD in non-obese adults
Multivariate logistic regression analysis was undertaken to evaluate risk factors for NAFLD. Ten variables including male gender, age, TG, TC, HDL-C, LDL-C, FPG, SUA, SCr, and BUN were entered into the original equation. Our results showed that all variables except for male gender, TC, SCr, and BUN remained in the final equation in non-obese subjects. In obese subjects, male gender, age, TG, FPG, and SUA remained in the final equation (Table 4 ). It was suggested that older age, hypertriglyceridemia, low HDL-C, elevated LDL-C and FPG, and hyperuricemia are closely associated with the risk for NAFLD in non-obese subjects. Remarkably, the non-obese group had higher NAFLD risk with increased SUA levels than the obese group (odds ratio, 2.559 and 95% confidence interval, 1.870-3.503 vs. odds ratio, 1.692 and 95% confidence interval, 1.371-2.087).
Correlation of SUA level with histological severity in non-obese adults To investigate the relationship between SUA level and different stages of NAFLD in non-obese adults, 93 NAFLD patients were divided into three groups according to biopsy result (Table 5 ). An analysis using one-way ANOVA followed by Dunnett's test revealed that none of the variables had significant differences between non-NASH and NASH groups, except for ALT and SUA. Notably, compared with the non-NASH group, SUA levels were significantly higher in indefinite NASH and NASH groups (344.53 ± 87.62 μmol/L vs. 397.71 ± 92.53 μmol/L and 403.21 ± 74.98 μmol/L, respectively). These results showed that non-obese adults had higher SUA levels as the inflammation advanced in NAFLD.
Relationship between SUA level and histopathological characteristics of NAFLD in non-obese adults
The score distribution of NAS and its components according to SUA level is shown in Figure 2 . The group with hyperuricemia had significantly higher NAS scores and more serious lobule inflammation than the normal group, whereas hepatic steatosis and ballooning degeneration had no significant difference between the two groups.
To get a deeper understanding of the relationship between SUA level and histopathological characteristics of NAFLD patients in the non-obese group, the impact of SUA level on the prevalence rates of different NAS scores and its components were studied. Our results showed that the prevalence rates of high NAS and lobule inflammation Significant values appear in boldface type. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; r, correlation coefficient; SCr, serum creatinine; TC, total cholesterol; TG, triglyceride. -, none data; β, partial regression coefficient; CI, confidence interval; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; OR, odds ratio.
score tended to increase as the SUA level increased, whereas this trend was not apparent in hepatic steatosis and ballooning degeneration (Fig. 3) . In Q4, the prevalence rates of NAS ≥ 5 reached 57.58%, and the prevalence rates of lobule inflammation score = 3 was 66.67% (Fig. 3) . It suggested that the inflammation of NAFLD tended to increase as the SUA level increased in non-obese subjects.
DISCUSSION
R ECENTLY, AN INCREASING number of studies have examined the significance of NAFLD in non-obese adults as NAFLD is increasingly prevalent in this group, with reported prevalence from 11.5% to 16.1%. 18, 19 In this study, we found that the prevalence of NAFLD was 14.88% in non-obese adults. The NAFLD patients had higher SUA levels than the control group. Previous studies showed that hyperuricemia is a significant and independent predictor of MetS, and MetS risk increases with increased serum uric acid levels. 20 Interestingly, the present study showed that SUA levels were significantly and positively correlated with BMI, TG, TC, LDL-C, ALT, SCr, and BUN, and the correlation coefficient in the non-obese group was higher than in the obese group. A meta-analysis suggested that increased SUA level is associated with an exacerbated risk of NAFLD. This increased risk is probably independent of conventional NAFLD risk factors. 21 In our study, we also found hyperuricemia was an risk factor of NAFLD. Nonobese adults have higher NAFLD risk with increased SUA levels than obese adults, suggesting that increased SUA concentrations, even within the normal range, are associated with the presence of NAFLD in non-obese subjects. Therefore, it is time to pay attention to the exact relationship between SUA level and NAFLD in non-obese adults.
Large clinical studies have indicated that hyperuricemia is associated with obesity, dyslipidemia, type 2 diabetes mellitus, and MetS. 22 There are also several studies suggesting that SUA level is significantly associated with NAFLD. 12, 13 However, few data are available about the relationship between SUA level and inflammation associated with NAFLD in non-obese adults. In 93 cases of non-obese biopsy-proven NAFLD we found that there were no significant differences between non-NASH and NASH groups, except for ALT and SUA levels. The SUA levels were significantly higher in indefinite NASH and NASH groups. These results showed that higher SUA levels correlated with increased inflammation in NAFLD. One of the possible explanations for the relationship †P-value was calculated using the Mann-Whitney U-test. ‡Compared with non-NASH, P < 0.05. §Compared with indefinite NASH, P < 0.05. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; TNF-α, tumor necrosis factor-α. between SUA level and the inflammation progression of NAFLD is that increased SUA is also linked to increased fat accumulation, hyperleptinemia, and insulin resistance. 11, 23 Uric acid becomes a strong oxidant in the environment of MetS. Serum uric acid could also stimulate the release of oxidants to promote oxidative stress by stimulating nicotinamide adenine dinucleotide phosphate oxidase and then be involved in the pathogenesis of NAFLD. More interestingly, in our study, patients with hyperuricemia had significantly higher NAS scores than those without hyperuricemia, and lobule inflammation was also more serious. The prevalence rates of high NAS and lobule inflammation tended to increase with increases in the SUA level. It suggested that the inflammation of NAFLD tended to increase as the SUA level increased. Recent studies discovered a close association between the inflammation development of NAFLD and many pathogenic events, including hepatic macrophage recruitment, activation of the innate immune system, and changes in lipid homeostasis. 24 The innate immune system has evolved mechanisms to detect the release of a subset of these molecules, called damage-associated molecular patterns (DAMPs). 25, 26 When macrophages sense the presence of DAMPs they are stimulated to produce proinflammatory cytokines that then induce inflammation. 27 It has been confirmed that uric acid is one of the important DAMPs. 28, 29 Does uric acid act as a DAMP by stimulating macrophages to produce pro-inflammatory cytokines and then induce inflammation progression in non-obese adults? Further research is needed.
In conclusion, the findings of the present study suggest that hyperuricemia is an independent risk factor for NAFLD, and SUA level is significantly associated with inflammation progression of NAFLD in non-obese adults. However, the precise mechanism requires further study. Intervention trials are needed to investigate whether the reduction of SUA levels favorably impacts NAFLD.
